2015 Antineoplastics

SESSION V OBJECTIVES: Drugs that interfere with protein function

  1. Describe the mechanisms of action (incl. resistance), pharmacokinetics and side effects of the currently approved signal transduction inhibitors (particularly inhibitors of BcrAbl), and explain the success of imatinib vs. gefitinib.

  2. Contrast conventional therapy for the treatment of CML with the use of STIs with respect to cure rates, remission and side effects.

Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 11-apr-15 9:39 AM